MedTrace Logo

TC Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Advanced Esophageal Cancer

NCT04471480 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2020-07-15

No results posted yet for this study

Summary

A Controlled Clinical Study of TC/PD-1 Inhibitors Combined With anlotinib as First-line Treatment for Advanced ESCC

Conditions

Interventions

DRUG

TC/PD-1 inhibitor/anlotinib

chemotherapy and immunotherapy plus antiangiogenic therapy

Sponsors & Collaborators

  • Dong Wang

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2022-08-31
Completion
2023-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04471480 on ClinicalTrials.gov